Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation

Frappaz, Didier; Bonneu, A.; Chauvot, P.; Edeline, Véronique; Giammarile, Francesco; Siles, S.; Wioland, M.; Gómez, F.

doi:10.1002/(sici)1096-911x(200004)34:4<237::aid-mpo1>3.0.co;2-j

Cited by 35 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To evaluate the prognostic effect of tumour burden at diagnosis and to be able to quantify response and define a partial response (50% reduction of all disease sites) by mIBG scan, semiquantitative scoring systems have been developed (Ady et al, 1995;Suc et al, 1996;Perel et al, 1999;Frappaz et al, 2000;Matthay et al, 2003b;Katzenstein et al, 2004;Messina et al, 2006;Lewington et al, 2009). This improves the concordance between readers, and enables one to differentiate a simple improvement with the disappearance of a lesion, or decreased intensity of lesions that can be subjective, from a significant response that would qualify as PR.…”

Section: Semi-quantitative Mibg Scoringmentioning

confidence: 99%

“…This system was subsequently shown to have good inter-observer concordance, but did not show prognostic value for outcome on further study (Frappaz et al, 2000). The Frappaz score (method 2) uses seven segments of the skeleton, and initially did not include soft tissue in the score, but noted it separately ( Figure 1B).…”

Section: Semi-quantitative Mibg Scoringmentioning

confidence: 99%

“…The score for method 2 was called an intensity score, and graded for each segment as: 0, no uptake; 1, doubtful uptake; 2, obvious but mild uptake; 3, strong uptake, with a maximum score of 21. A separate qualitative 'diffusion' score was entered as 0 if there was no uptake, 1 if uptake was spotty and 2 if uptake was diffuse, with a maximum score of 14 (Frappaz et al, 2000). Perel et al (1999) published another minor variation on the Curie score, in which the skeleton was divided into 10 rather than 9 zones (the skull was divided into the calvarium and the base of the skull, as in the Frappaz method), and soft tissue involvement was ignored.…”

Section: Semi-quantitative Mibg Scoringmentioning

confidence: 99%

“…Previous studies have indicated that a positive mIBG scan after induction chemotherapy or just before myeloablative therapy may be a prognostic marker for a high likelihood of relapse (Ladenstein et al, 1998;Perel et al, 1999;Schmidt et al, 2008). Several publications have reported the use of semi-quantitative scoring systems to increase the precision and inter-observer reliability of this test, with success in correlating the results of mIBG scans with early response and event-free survival in some, but not all, reports (Ady et al, 1995;Suc et al, 1996;Frappaz et al, 2000;Hero et al, 2001;Matthay et al, 2003b;Katzenstein et al, 2004). As treatment of stage 4 neuroblastoma continues to be a challenge, with a high rate of relapse in bone and bone marrow, it is essential to have a quantitative and reliable measure of response in bone metastases to test the activity of new therapies for this disease (Messina et al, 2006).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Neuroblastoma is an embryonic tumour of the sympathetic nervous system, metastatic in half of the patients at diagnosis, with a high preponderance of osteomedullary disease, making accurate evaluation of metastatic sites and response to therapy challenging. Metaiodobenzylguanidine (mIBG), taken into cells via the norepinephrine transporter, provides a sensitive and specific method of assessing tumour in both soft tissue and bone sites. The goal of this report was to develop consensus guidelines for the use of mIBG scans in staging, response assessment and surveillance in neuroblastoma. METHODS: The International Neuroblastoma Risk Group (INRG) Task Force, including a multidisciplinary group in paediatric oncology of North and South America, Europe, Oceania and Asia, formed a subcommittee on metastatic disease evaluation, including expert nuclear medicine physicians and oncologists, who developed these guidelines based on their experience and the medical literature, with approval by the larger INRG Task Force. RESULTS: Guidelines for patient preparation, radiotracer administration, techniques of scanning including timing, energy, specific views, and use of single photon emission computed tomography are included. Optimal timing of scans in relation to therapy and for surveillance is reviewed. Validated semi-quantitative scoring methods in current use are reviewed, with recommendations for use in prognosis and response evaluation. CONCLUSIONS: Metaiodobenzylguanidine scans are the most sensitive and specific method of staging and response evaluation in neuroblastoma, particularly when used with a semi-quantitative scoring method. Use of the optimal techniques for mIBG in staging and response, including a semi-quantitative score, is essential for evaluation of the efficacy of new therapy.

show abstract

Section: Semi-quantitative Mibg Scoringmentioning

confidence: 99%

Section: Semi-quantitative Mibg Scoringmentioning

confidence: 99%

Section: Semi-quantitative Mibg Scoringmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In order to evaluate the prognostic effects and quantify efficacy of therapy, numerous semiquantitative scores have emerged (Ady et al, 1995;Frappaz et al, 2000;Messina et al, 2006;Lewington et al, 2009;Yanik et al, 2013;Decarolis et al, 2013) although none of them has shown to be superior to the others for quantification of response to the treatment (Matthay et al, 2010). In 2004, nuclear medicine physicians and oncologists of the major cooperative groups from North America, Australia, New Zealand, Europe, China and Japan formed the International Neuroblastoma Risk Group (INRG).…”

Section: Introductionmentioning

confidence: 99%

QUANTITATIVE APPROACH TO ASSIST NEUROBLASTOMA ASSESSMENT BY MEASURING I-123 mIBG UPTAKE IN SCINTIGRAPHIC IMAGES

et al. 2015

View full text Add to dashboard Cite

Whole-body 123 I-Metaiodobenzylguanidine (mIBG) scintigraphy is used as the primary image modality in neuroblastoma detection. It is the most sensitive and specific method for staging and response evaluation. Validated semi-quantitative scoring methods with low interobserver variability and high reproducibility have shown to be indispensable for the evaluation of response to therapy. However, low resolution, noise and acquisition difficulties, specially in children, make low definition scans. These facts increase observer dependent interpretations that limit assessment and complicate to put a scoring method succesfully into practice. It is essential to have an objective and reliable measure of response to test the activity of therapies. In this paper we propose the use of a quantitative observer-independent measurement of the strength of uptake to be used as an additional tool for assisting the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) semi-quantitative scoring method. This is the scoring method recommended by the SIOPEN Nuclear Medicine and Physics Committee, in collaborative work with the Children's Oncology Group, as the standard one for acquiring and reporting diagnostic paediatric mIBG scans across Europe. Our proposed method is based on the ratio between the amount of specific uptake at tumours and the amount of non-specific uptake at SIOPEN anatomical sectors which has shown to be constant in all the scans of the patients.

show abstract

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Bleeker¹,

Tytgat

Adam

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Neuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood. Neuroblastoma cells have the unique capacity to accumulate Iodine‐123‐metaiodobenzylguanidine (¹²³I‐MIBG), which can be used for imaging the tumour. Moreover, ¹²³I‐MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localization of skeletal lesions. If these are present, MIBG follow‐up scans are used to assess the patient's response to therapy. However, the sensitivity and specificity of ¹²³I‐MIBG scintigraphy to detect neuroblastoma varies according to the literature. Prognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of ¹²³I‐MIBG scans. Due to its clinical use and importance, it is necessary to determine the exact diagnostic accuracy of ¹²³I‐MIBG scintigraphy. In case the tumour is not MIBG avid, fluorine‐18‐fluorodeoxy‐glucose ( 18 F‐FDG) positron emission tomography (PET) is often used and the diagnostic accuracy of this test should also be assessed. Objectives Primary objectives: 1.1 To determine the diagnostic accuracy of ¹²³I‐MIBG (single photon emission computed tomography (SPECT), with or without computed tomography (CT)) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. 1.2 To determine the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old, i.e. an add‐on test. Secondary objectives: 2.1 To determine the diagnostic accuracy of 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. 2.2 To compare the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) and 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between included studies. ¹²³I‐MIBG (SPECT‐CT) scintigraphy was the comparator test in this case. Search methods We searched the databases of MEDLINE/PubMed (1945 to 11 September 2012) and EMBASE/Ovid (1980 to 11 September 2012) for potentially relevant articles. Also we checked the reference lists of relevant articles and review articles, scanned conference proceedings and searched for unpublished studies by contacting researchers involved in this area. Selection criteria We included studies of a cross‐sectional design or cases series of prove...

show abstract

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation

Cited by 35 publications

References 13 publications

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

QUANTITATIVE APPROACH TO ASSIST NEUROBLASTOMA ASSESSMENT BY MEASURING I-123 mIBG UPTAKE IN SCINTIGRAPHIC IMAGES

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Contact Info

Product

Resources

About